Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group) announced today that it will have two Late-Breaking Research Forum Presentations at the American Academy of Dermatology Annual Meeting in Washington D.C.

“We’re honored that the research conducted with two of our in-office devices, the Cellfina™ System and Ultherapy, was chosen for Late-Breaking Research Forum Presentations, which highlight the latest ground-breaking observations in the market. Both devices have proven track records with patients and physicians; and continuing to study their use in order to elevate the experience of our customers is important to Merz,” Patrick Urban, U.S. Head of Merz Aesthetics Device Division, said. “The Cellfina™ System data is especially notable, showcasing that the device provides long-term improvements in the appearance of cellulite and no reduction in treatment benefits, making it the longest-lasting option for cellulite available on the market.”

The presentation (Abstract ID 3821) for the Cellfina™ System, titled “Multicenter Pivotal Study of the Safety and Effectiveness of a Tissue Stabilized-Guided Subcision Procedure for the Treatment of Cellulite: 3 Year Update” will highlight new outcome data up to 3 years from the pivotal prospective, multi-centered study (Kaminer et al. Multicenter pivotal study of vacuum-assisted precise tissue release for the treatment of cellulite. Dermatol Surg 2015;41:336-347). Presenter: Michael Kaminer, MD, FAAD; Skincare Physicians; Chestnut Hill, MA.

The second presentation (Abstract ID 3807) is titled the “Evaluation of the Safety and Efficacy of Microfocused Ultrasound with Visualization (MFU-V) for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea.” Presenter: Rosalyn George, MD, FAAD; Wilmington Dermatology Center; Wilmington, NC.

Both late-breaking presentations will be held on March 5, 2016, at the Late-Breaking Research Forum for Procedural Dermatology (F065) at 2:24 pm and 2:36 pm in Room 146C.

For more information about Ultherapy and the Cellfina™ System, physicians and media can visit the Merz Aesthetics booth at AAD on either March 4 at 1:30 pm for a presentation from Deanne M Robinson, MD of the Connecticut Dermatology Group in Milford, Conn., or on March 5 at 1:30 pm for a presentation from Sabrina G Fabi, MD, FAAD, FAACS, of the Cosmetic Laser Dermatology in San Diego, Calif.

For full Cellfina product and safety information, visit

About Merz Aesthetics

Merz Aesthetics is a division of Merz North America, a specialty healthcare company that develops and commercializes treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. As part of the Merz Pharma Group of companies, our ambition is to become the most admired, trusted and innovative aesthetics and neurotoxin company. By developing products that improve patients’ health and help them to live better, feel better and look better, Merz will continue to make significant contributions to the well-being of individuals around the world. Merz Aesthetics provides a range of treatment options, including devices, injectables and skincare, that enable physicians to use Merz technologies to treat a variety of patients and concerns. For more information about Merz Aesthetics and their U.S. product portfolio, please visit

Download File:
03.04.2016 [ 0 KB ]

Press Contact

Merz North America

Emily Browder
Corporate Communications


Phone: +1 919.582.8114

Merz in the Americas

Merz has a direct presence in six countries in the Americas, as well as a network of selected professional distribution partners in South and Central America and the Caribbean. Merz in the Americas is headquartered in Raleigh, North Carolina, and has facilities in Mesa, Arizona, Franksville, Wisconsin as well as offices in Toronto, Canada, Mexico City, Bogotá, Colombia, São Paolo, Brazil and Buenos Aires, Argentina.

Merz Worldwide

With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at

Media Contact – Global

Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466

Media Contact – North America

Merz North America, Inc.
Corporate Communications
Emily Browder
Phone: +1 919.582.8114